Effect of Jianpi-yangwei decoction on gut fungi in the patients with gastric cancer undergoing chemotherapy
Journal Title: Traditional Medicine Research - Year 2021, Vol 6, Issue 2
Abstract
Background: Our previous study shows that the empirical formula of Chinese medicine Jianpi-yangwei decoction (JYD) can improve the quality of life in patients with gastric cancer undergoing chemotherapy by increasing beneficial gut bacteria and decreasing harmful bacteria. The present study aims to investigate the effect of JYD on gut fungi in patients with gastric cancer undergoing chemotherapy. Methods: A total of 73 patients with gastric cancer undergoing chemotherapy were recruited. Twenty-nine patients in the chemotherapy group were given standard chemotherapy and 44 patients in the observation group were given JYD plus standard chemotherapy. A control group (55 cases) was recruited from the healthy medical examiners. After 3 months of treatment, life-quality score was evaluated and fecal microbiota was tested by high-throughput sequencing based on the 18S rRNA gene. Results: After treatment, life-quality score in the observation group was significantly lower than that in the chemotherapy group (P < 0.05). There was no significant difference between the observation and control groups’ diversity and richness indices of intestinal fungi. The Chao index for intestinal fungi in the chemotherapy group was significantly lower than that in the observation group (P < 0.05). There was a significant difference between the control and chemotherapy groups in the intestinal fungi according to Shannon and Simpson indices (P < 0.05). Linear discriminant analysis effect size analysis showed no significant differences among the three groups, but significant difference in intestinal fungi was observed between the observation group and the chemotherapy group. At the genus level, the relative abundance of the Aspergillus genus in the observation and control groups was significantly lower (P < 0.05), the relative abundance of the Cutaneotrichosporon, Galactomyces, and Ganoderma genus taxa was significantly higher compared with those in the chemotherapy group (P < 0.05), and there was no significant difference between the observation group and control group. Conclusion: JYD can ameliorate chemotherapy-induced fungal dysbacteriosis in patients with gastric cancer undergoing chemotherapy and improve the quality of life of patients.
Authors and Affiliations
Chun-Jie Xiang, Shuo Xu1, Juan Wu, Yu-Heng Peng, Rui Shen, Wei Dong, Rui-Ping Wang, Zhen Zhan, Jun-Feng Zhang
Keywords
Related Articles
- EP ID EP691379
- DOI 10.12032/TMR20200603190
- Views 150
- Downloads 0
Can hip abduction reduce the risk of femoral head necrosis deteriorated into osteoarthritis? A 3D finite element analysis
Objective: The purpose of this study was to investigate biomechanical behavior changes of femoral head necrosis (FHN) by increasing lower extremity abduction (LEA) angle, offering scientific basis on choosing the LEA pro...
Effect of Ganduqing Granule on metabolic disorder and liver dysfunction in patients with chronic hepatitis B
Objective: This study investigated the potential mechanisms of Ganduqing Granule (GDQG) in improving the liver function in patients with chronic hepatitis B (CHB). Methods: Plasma samples from 30 healthy volunteers and 3...
Nephrotoxicity and carcinogenesis of aristolochic acids and their derivates
Aristolochic acids (AAs), a natural mixture of 8-methoxy-6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid (AAI) and 6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid (AAII), derived from aristolochiaceae s...
Toxicological advances of traditional medicine in 2020
There were many researches concerning toxicology of traditional medicine and active natural products during the past 12 months. This annual toxicology review summarized different toxic analysis methods of traditional med...
Chlorogenic acid may be a potent inhibitor of dimeric SARS-CoV-2 main protease 3CLpro: an in silico study
Background: Since the emergence of coronavirus disease 2019 to date, there is no available approved drug or definitive treatment for coronavirus disease 2019 viral infection, and the identification of novel hits against...